Junia V Melo
Overview
Explore the profile of Junia V Melo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
2992
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cerny-Reiterer S, Meyer R, Herrmann H, Peter B, Gleixner K, Stefanzl G, et al.
Oncotarget
. 2014 Apr;
5(5):1198-211.
PMID: 24681707
Heat shock proteins (Hsp) are increasingly employed as therapeutic targets in oncology. We have shown that Hsp32, also known as heme oxygenase-1 (HO-1), serves as survival factor and potential target...
12.
Rix U, Colinge J, Blatt K, Gridling M, Remsing Rix L, Parapatics K, et al.
PLoS One
. 2013 Oct;
8(10):e77155.
PMID: 24130846
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is in part driven by the tyrosine kinase bcr-abl, but imatinib does not produce long-term remission. Therefore, second-generation ABL inhibitors are currently in...
13.
Ross D, Branford S, Seymour J, Schwarer A, Arthur C, Yeung D, et al.
Blood
. 2013 May;
122(4):515-22.
PMID: 23704092
Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 chronic-phase CML patients...
14.
Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo J, et al.
Nat Rev Cancer
. 2012 Oct;
12(11):767-75.
PMID: 23051844
The cancer stem cell (CSC) concept has important therapeutic implications, but its investigation has been hampered both by a lack of consistency in the terms used for these cells and...
15.
Lipka D, Wagner M, Dziadosz M, Schnoder T, Heidel F, Schemionek M, et al.
PLoS One
. 2012 Jul;
7(7):e40853.
PMID: 22815843
Clinical development of imatinib in CML established continuous target inhibition as a paradigm for successful tyrosine kinase inhibitor (TKI) therapy. However, recent reports suggested that transient potent target inhibition of...
16.
Roy S, Jorgensen H, Roy P, Abed El Baky M, Melo J, Strathdee G, et al.
Br J Haematol
. 2012 Mar;
157(4):446-56.
PMID: 22372463
MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density,...
17.
Melo J, Ross D
Hematology Am Soc Hematol Educ Program
. 2011 Dec;
2011:136-42.
PMID: 22160025
Patients with chronic myeloid leukemia (CML) who have achieved a complete molecular response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often ask whether it is necessary...
18.
Carella A, Goldman J, Martinelli G, Melo J, Perrotti D
Haematologica
. 2011 Dec;
96(12):1737-9.
PMID: 22147770
No abstract available.
19.
Schultheis B, Nijmeijer B, Yin H, Gosden R, Melo J
Leuk Res
. 2011 Oct;
36(3):271-4.
PMID: 22018447
Imatinib should be avoided in women planning to become pregnant or during pregnancy, due to a higher risk of congenital malformations. However, it is not known whether imatinib affects future...
20.
Tanaka R, Kimura S, Ashihara E, Yoshimura M, Takahashi N, Wakita H, et al.
Cancer Lett
. 2011 Sep;
312(2):228-34.
PMID: 21890264
ABL tyrosine kinase inhibitor (TKI), imatinib is used for BCR-ABL(+) leukemias. We developed an automatic method utilizing guanine-quenching probes (QP) to detect 17 kinds of mutations frequently observed in imatinib-resistance....